High-purity active pharmaceutical ingredients manufactured under rigorous cGMP protocols.
Abiraterone Acetate (CAS No. 154229-18-2) represents a cornerstone targeted therapeutic in modern neuroendocrine and oncological pharmacology. Chemically designated as (3β)-17-(3-pyridinyl)androsta-5,16-dien-3-yl acetate, this steroidal prodrug converts in vivo into its active metabolite, Abiraterone, which serves as a potent, selective, and irreversible inhibitor of the enzyme 17α-hydroxylase/C17,20-lyase (CYP17A1). By blocking this crucial enzymatic complex within the adrenal glands, testes, and prostatic tumor tissues, Abiraterone Acetate halts the biosynthesis of testicular and extragonadal androgens that fuel metastatic castration-resistant prostate cancer (mCRPC).
The chemical synthesis roadmap of commercial-grade Abiraterone Acetate typically initiates from Dehydroepiandrosterone (DHEA) or its acetate derivative. The key synthetic challenge lies in the regiospecific transformation of the C-17 ketone into an enol triflate intermediate, followed by a transition-metal-catalyzed cross-coupling with diethyl(3-pyridyl)borane or 3-pyridylboronic acid. Advanced Industry 4.0 chemical synthesis platforms leverage continuous-flow microreactors for the triflation and coupling steps to suppress toxic dimer impurities and unreacted steroidal bypass products.
Looking toward future therapeutic applications, research is expanding beyond classic mCRPC. Clinical trials are investigating combination therapies involving Abiraterone Acetate paired with Poly (ADP-ribose) Polymerase (PARP) inhibitors, androgen receptor pathway inhibitors (ARPIs), and immune checkpoint modulators. As formulation science evolves, micronized and nano-milled Abiraterone Acetate formulations are emerging to enhance oral absorption, reduce food-effect variability, and lower the required daily clinical dosage.
The global healthcare sector faces unprecedented supply chain volatilities, particularly regarding high-potency active pharmaceutical ingredients (HPAPIs) essential for oncology treatment regimes. Disruptions in primary intermediate sourcing, sudden regulatory shifts, and capacity bottlenecks frequently jeopardize patient access to life-saving medicines like Abiraterone Acetate.
To establish systemic supply security, multi-national pharmaceutical enterprises, contract development and manufacturing organizations (CDMOs), and institutional buyers require macro-level strategic partnerships. A resilient supply model encompasses full vertical integration—from basic petro-chemical precursors to steroidal intermediates (such as 16-DPA and DHEA), culminating in certified cGMP bulk API synthesis.
Mitigating regional geopolitical risks by maintaining redundant reaction trains and raw material buffers across geographically diverse plants.
State-of-the-art isolators and containment facilities compliant with OEL Class 4 (<1 μg/m³) standards protecting operators and environment.
Providing complete technology transfer packages, dossier licensing (CTD format), and bioequivalence data for rapid market entry.
Gentolex Group’s modern manufacturing infrastructure embodies China's transition into high-value, tech-driven pharmaceutical production. Operating across an expansive overall factory construction area of 250,000 square meters built strictly under international standard frameworks, our facilities deliver unmatched scalability, operational agility, and cost-effectiveness.
Industry 4.0 integration allows real-time telemetry monitoring of critical process parameters (CPPs) such as reaction temperature, agitation velocity, solvent evaporation rates, and crystallizer supersaturation ratios. This digital control architecture guarantees batch-to-batch consistency and minimizes structural impurity generation.
Procuring Abiraterone Acetate API for commercial drug manufacturing demands strict adherence to global regulatory standards. Qualified API suppliers must satisfy multi-faceted regulatory audits and provide complete documentation packages.
Gentolex provides comprehensive regulatory support, ensuring seamless filing with global health authorities including the US FDA, EDQM, NMPA, PMDA, and ANVISA. Our technical dossiers include:
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries. Recognizing the nuance of localized pharmaceutical registration and distribution, dedicated regional representative offices have been established in key emerging markets including Mexico and South Africa.
Our core capabilities encompass a comprehensive spectrum of pharmaceutical supply and engineering solutions:
Flexible, scalable, and cost-effective chemical solutions manufactured under cGMP standard long-term collaborations.
An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective solutions for international client requirements.
Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations. Documents and Certificates are supported to customers worldwide.
Comprehensive R&D services including custom peptide modification, route selection, process validation, scale-up synthesis, and analytical method development.
For those clients who prefer to avoid the complexity of dealing with multiple points of contact, we provide extra customized procurement services with the most superior and comprehensive supply chain sources.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa. Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
Strict compliance with global regulatory frameworks and cGMP standards.
Latest updates in peptide active pharmaceutical ingredients and regulatory intelligence.
Introduction to Selank Acetate API: Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient (API) composed of the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). Originally developed through neuropharmacological research, Selank is a derivative of the endogenous...
View Details
Trusted Thymosin Beta-4 API Manufacturer and Global Peptide Supplier: As a professional Thymosin Beta-4 API manufacturer and supplier, we provide high-quality Thymosin Beta-4 peptide API solutions for biotechnology companies, pharmaceutical research organizations, and li...
View Details
Introduction: BPC-157 API is a synthetic pentadecapeptide that has gained increasing attention in peptide research due to its potential biological activities related to tissue repair, gastrointestinal protection, angiogenesis, and inflammatory regulation. As a peptide ac...
View Details
With the continuous development of neuroscience, peptide technology, and life science research, neuroactive peptides have become an important area of scientific investigation. Semax, a synthetic peptide derived from an ACTH fragment, has attracted attention among researchers due to its unique mol...
View Details
SS-31 (Elamipretide) API: SS-31 API, also known as Elamipretide, MTP-131, Bendavia, and SS31, is a synthetic mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane. By stabilizing mitochondrial structure and supporting cellular bioenergetics, SS-31 ha...
View DetailsTechnical and commercial answers for pharmaceutical buyers, QA/RA specialists, and formulation scientists.
Explore our full range of high-purity custom peptides and specialized chemical building blocks.
